Literature DB >> 3864173

A Negative Symptom Rating Scale.

A C Iager, D G Kirch, R J Wyatt.   

Abstract

Renewed interest in the role of negative symptoms in "defect state" schizophrenia calls for the design of a standardized, easy to use, reliable, and valid instrument to assess these aspects of psychopathology. In order to measure negative symptoms, we developed the Negative Symptom Rating Scale (NSRS). We report on the design, interrater reliability, and construct-validation of NSRS against the most frequently used negative symptom scales or subscales. In summary, the NSRS is a short, sensitive, highly specific, reliable, and apparently valid instrument for measuring negative symptoms in schizophrenia.

Entities:  

Mesh:

Year:  1985        PMID: 3864173     DOI: 10.1016/0165-1781(85)90025-3

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  9 in total

Review 1.  Positive-negative symptom assessment in schizophrenia: psychometric issues and scale comparison.

Authors:  S R Kay
Journal:  Psychiatr Q       Date:  1990

Review 2.  Effect of neuroleptics on positive and negative symptoms and the deficit state.

Authors:  J Angst; H H Stassen; B Woggon
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 3.  Negative symptoms, defect state and Huber's basic symptoms: a comparison of the concepts.

Authors:  J de Leon; W H Wilson; G M Simpson
Journal:  Psychiatr Q       Date:  1991

4.  Hypofrontality on topographic EEG in schizophrenia. Correlations with neuropsychological and psychopathological parameters.

Authors:  W F Gattaz; S Mayer; P Ziegler; M Platz; T Gasser
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

5.  Psychosis with good prognosis in Afro-Caribbean people now living in the United Kingdom.

Authors:  K McKenzie; J van Os; T Fahy; P Jones; I Harvey; B Toone; R Murray
Journal:  BMJ       Date:  1995-11-18

Review 6.  Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia.

Authors:  H J Möller; H M van Praag; B Aufdembrinke; P Bailey; T R Barnes; J Beck; H Bentsen; F X Eich; L Farrow; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

7.  Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia.

Authors:  Christopher Jones; David Hacker; Jun Xia; Alan Meaden; Claire B Irving; Sai Zhao; Jue Chen; Chunhu Shi
Journal:  Cochrane Database Syst Rev       Date:  2018-12-20

Review 8.  Cortical gyrification in schizophrenia: current perspectives.

Authors:  Yukihisa Matsuda; Kazutaka Ohi
Journal:  Neuropsychiatr Dis Treat       Date:  2018-07-19       Impact factor: 2.570

Review 9.  Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia.

Authors:  Katina Aleksovska; Emanuele Leoncini; Stefano Bonassi; Alfredo Cesario; Stefania Boccia; Alessandra Frustaci
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.